[go: up one dir, main page]

WO2008064815A3 - Préparation pour l'administration transdermique de galanthamine - Google Patents

Préparation pour l'administration transdermique de galanthamine Download PDF

Info

Publication number
WO2008064815A3
WO2008064815A3 PCT/EP2007/010112 EP2007010112W WO2008064815A3 WO 2008064815 A3 WO2008064815 A3 WO 2008064815A3 EP 2007010112 W EP2007010112 W EP 2007010112W WO 2008064815 A3 WO2008064815 A3 WO 2008064815A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
galanthamine
transdermally administering
transdermally
administering galanthamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/010112
Other languages
German (de)
English (en)
Other versions
WO2008064815A2 (fr
Inventor
Frank Becher
Thomas Hille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of WO2008064815A2 publication Critical patent/WO2008064815A2/fr
Publication of WO2008064815A3 publication Critical patent/WO2008064815A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une préparation pour l'administration transdermique de galanthamine, caractérisée en ce que la galanthamine, ou l'un de ses sels pharmaceutiquement acceptable, est amené en l'état de résorption transdermique dans une émulsion non huileuse.
PCT/EP2007/010112 2006-12-01 2007-11-22 Préparation pour l'administration transdermique de galanthamine Ceased WO2008064815A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006056783.8 2006-12-01
DE102006056783A DE102006056783A1 (de) 2006-12-01 2006-12-01 Zubereitung zur transdermalen Verabreichung von Galanthamin

Publications (2)

Publication Number Publication Date
WO2008064815A2 WO2008064815A2 (fr) 2008-06-05
WO2008064815A3 true WO2008064815A3 (fr) 2008-07-17

Family

ID=39247230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/010112 Ceased WO2008064815A2 (fr) 2006-12-01 2007-11-22 Préparation pour l'administration transdermique de galanthamine

Country Status (2)

Country Link
DE (1) DE102006056783A1 (fr)
WO (1) WO2008064815A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002402A2 (fr) * 2002-05-21 2004-01-08 Nastech Pharmaceutical Company Inc. Administration d'inhibiteurs d'acetylcholinesterase au liquide cephalorachidien spinal
US20040185170A1 (en) * 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
US20050074487A1 (en) * 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
WO2005039531A1 (fr) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Formulation pharmaceutique transdermique visant a reduire les residus sur la peau
WO2005102268A2 (fr) * 2004-04-22 2005-11-03 Sanochemia Pharmazeutika Ag Inhibiteurs de la cholinesterase inclus dans des liposomes, leur production et leur utilisation
WO2007016766A1 (fr) * 2005-08-05 2007-02-15 Nuvo Research Inc. Formulation pour l'administration transdermique de medicaments

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
HU227182B1 (en) * 2000-03-06 2010-09-28 Andras Javor Lecitin-ascorbic acid combination

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074487A1 (en) * 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
WO2004002402A2 (fr) * 2002-05-21 2004-01-08 Nastech Pharmaceutical Company Inc. Administration d'inhibiteurs d'acetylcholinesterase au liquide cephalorachidien spinal
US20040185170A1 (en) * 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
WO2005039531A1 (fr) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Formulation pharmaceutique transdermique visant a reduire les residus sur la peau
WO2005102268A2 (fr) * 2004-04-22 2005-11-03 Sanochemia Pharmazeutika Ag Inhibiteurs de la cholinesterase inclus dans des liposomes, leur production et leur utilisation
WO2007016766A1 (fr) * 2005-08-05 2007-02-15 Nuvo Research Inc. Formulation pour l'administration transdermique de medicaments

Also Published As

Publication number Publication date
DE102006056783A1 (de) 2008-06-05
WO2008064815A2 (fr) 2008-06-05

Similar Documents

Publication Publication Date Title
WO2010150995A3 (fr) Compositions de traitement de la dépendance aux drogues et d'amélioration du comportement lié aux dépendances
WO2008070149A3 (fr) Promédicaments et procédés pour les fabriquer et les utiliser
WO2007126964A3 (fr) Inhibiteurs de kinase
EP2562177A3 (fr) Promédicaments de buprenorphine administrables de façon transdermique et leurs compositions empêchant une utilisation abusive
WO2007135193A3 (fr) Forme pharmaceutique orale multimicroparticulaire a liberation prolongee comprenant des moyens anti-mesusage et resistant a l'alcool
WO2007092755A3 (fr) Traitement de l'insuffisance et de la deficience de vitamine d avec de la 25-hydroxyvitamine d2 et de la 25-hydroxyvitamine d3
WO2008061226A3 (fr) Formulations de topiramate à libération prolongée
WO2010041017A3 (fr) Émulsions gélifiées pouvant être mâchées
WO2009045795A3 (fr) Formulations galéniques de composés organiques
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
WO2010090494A3 (fr) Utilisation médicale de dérivés d'acide 5-benzylaminosalicylique ou de sels correspondants
EP1902715A3 (fr) Utilisation de la palipéridone pour le traitement de patients psychiatriques avec une fonction hépatique déficiente
WO2005107711A3 (fr) Procede et composition permettant de traiter la rhinite
WO2007133796A3 (fr) Procédés et compositions de traitement de l'apnée du sommeil
WO2009045053A3 (fr) Sensibilisant du cancer comprenant un acide chlorigénique
WO2008051527A3 (fr) Libération prolongée d'agents pour la gestion d'une douleur localisée
WO2007018588A8 (fr) Composition pharmaceutique stable comprenant la forme iv de linézolide
WO2008061671A3 (fr) Utilisation d'un acide indazoleméthoxyalcanoïque dans la préparation d'une composition pharmaceutique
WO2007134085A3 (fr) Composés thérapeutiques
WO2008063847A3 (fr) Méthode de traitement de l'autisme
EP2392335A3 (fr) Utilisation de 24-norUDCA
WO2008125940A3 (fr) Nanoparticules comprenant un médicament non cristallin
WO2008064815A3 (fr) Préparation pour l'administration transdermique de galanthamine
WO2005120518A3 (fr) Utilisation d'analogues d'atp pour le traitement des maladies cardio-vasculaires
WO2006128152A3 (fr) Procede de traitement et de prevention de l'opacification de la capsule posterieure

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07856217

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007856217

Country of ref document: EP

122 Ep: pct application non-entry in european phase

Ref document number: 07856217

Country of ref document: EP

Kind code of ref document: A2